Epratuzumab I-131

Drug Profile

Epratuzumab I-131

Alternative Names: Anti-CD22 monoclonal antibody LL2-I-131; IMMU LL2-I-131; ImmuRAIT-LL2-I -131; LymphoCide I -131; Monoclonal antibody LL2-I-131

Latest Information Update: 11 Oct 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunomedics
  • Developer Immunomedics; Repligen Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 08 Aug 2001 US patent issued to Immunomedics covering the engineering of a glycosylation site on anti-CD22 antibodies for the purpose of attaching drugs or isotopes without affecting targeting
  • 24 Feb 2000 A phase I study in non-Hodgkin's lymphoma has been added to the therapeutic trials section
  • 01 Oct 1997 Immunomedics has licensed production technology for LymphocideTM from Repligen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top